Statement: Response to EHRC report on disabled access at Premier League grounds

Wednesday 16 May, 2018

Muscular Dystrophy UK has responded to a report by the Equality and Human Rights Commission (EHRC), which looks at disabled access at Premier League football clubs.

The report, published today, looks at the progress current and former Premier League clubs have made in making their grounds accessible for disabled fans. It highlights the number of wheelchair spaces at their stadiums, as well as those with Changing Places toilets.

It also sets out EHRC’s recommendations, and details the work it is doing with clubs, including Chelsea, Burnley, Watford, Crystal Palace, Hull City, Manchester United and Sunderland.

Lauren West, Trailblazers Manager at Muscular Dystrophy UK, said: “Some Premier League clubs are now taking the needs of disabled fans seriously, but it is important not to simply see access as about having enough wheelchair spaces. When we surveyed disabled sports fans, half had had to sit away from friends and families, and a third had the intimidating experience of sitting with opposing teams. Clubs can work with disabled sports fans like us to bring their stadiums up to the agreed standard, with more seating and better facilities for disabled fans, and to carry out accessibility audits to make sure they work in practice.”

The report can be read in full here.

- Ends -

Notes to editors

About muscle-wasting conditions

  • More than 70,000 children and adults in the UK have a muscle-wasting condition.
  • Muscle-wasting conditions may be inherited or strike out of the blue. These conditions cause muscles to weaken and waste over time, leading to increasingly severe disability. Some affect the heart and muscles vital for breathing, cutting lives short.

Muscular Dystrophy UK

  • Muscular Dystrophy UK is the charity for 70,000 children and adults living with muscle-wasting conditions. We provide vital information, advice and support to help people live as independently as possible. We accelerate progress in research and drive the campaign for access to emerging treatments.
Keep in touch